| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633 | |
| Description | CD19 molecule | |||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding | |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | Entrez:933 MIM:107266 HGNC:HGNC:1643 Ensembl:ENSG00000012124 AllianceGenome:HGNC:1643 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | CD22 molecule | |||||
| GTO ID | GTC2879 |
| Trial ID | NCT05168748 |
| Disease | Acute Lymphoblastic Leukemia |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | IMJ995 |
| Phase | Phase1 |
| Recruitment status | Withdrawn |
| Title | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia |
| Year | 2021 |
| Country | Switzerland |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | CIMJ995A12101|2021-000677-89 |
| Cohort 1 | |||||||||
|
|||||||||